Stephen Priebe, Stock Yards Bancorp, Inc. (SYBT)’s insider Purchased 117 Shares; Cleveland Biolabs (CBLI) Sellers Increased By 0.96% Their Shorts

Cleveland BioLabs, Inc. (NASDAQ:CBLI) Logo

Cleveland Biolabs Inc (NASDAQ:CBLI) had an increase of 0.96% in short interest. CBLI’s SI was 21,000 shares in May as released by FINRA. Its up 0.96% from 20,800 shares previously. With 14,800 avg volume, 1 days are for Cleveland Biolabs Inc (NASDAQ:CBLI)’s short sellers to cover CBLI’s short positions. The SI to Cleveland Biolabs Inc’s float is 0.67%. The stock decreased 1.04% or $0.03 during the last trading session, reaching $2.85. About 3,659 shares traded. Cleveland BioLabs, Inc. (NASDAQ:CBLI) has risen 101.92% since May 1, 2017 and is uptrending. It has outperformed by 90.37% the S&P500.

Stock Yards Bancorp, Inc. operates as the bank holding firm for Stock Yards Bank & Trust Company that provides commercial and personal banking services in Louisville, Indianapolis, and Cincinnati. The company has market cap of $851.82 million. The Company’s deposit products include non-interest and interest bearing demand deposits, savings deposits, certificates of deposit, money market deposits, and time deposits. It has a 22.59 P/E ratio. The companyÂ’s loan portfolio comprises commercial and industrial, construction and development, undeveloped land, real estate mortgage, and consumer loans; and originates and sells single-family residential mortgages.

Investors sentiment increased to 1.53 in 2017 Q4. Its up 0.27, from 1.26 in 2017Q3. It improved, as 6 investors sold Stock Yards Bancorp, Inc. shares while 26 reduced holdings. 14 funds opened positions while 35 raised stakes. 10.62 million shares or 0.64% more from 10.56 million shares in 2017Q3 were reported. Swiss Commercial Bank has invested 0% in Stock Yards Bancorp, Inc. (NASDAQ:SYBT). Bancorporation Of Ny Mellon Corporation reported 197,065 shares. Parallax Volatility Advisers L P accumulated 0% or 3,318 shares. 101 are held by Royal Bank & Trust Of Canada. Fenimore Asset has invested 0.15% in Stock Yards Bancorp, Inc. (NASDAQ:SYBT). 312,263 were reported by Mutual Of America Management Lc. Bb&T Corporation has 0.01% invested in Stock Yards Bancorp, Inc. (NASDAQ:SYBT) for 7,353 shares. Rhumbline Advisers has invested 0% in Stock Yards Bancorp, Inc. (NASDAQ:SYBT). Smith Asset Mgmt L P owns 0.01% invested in Stock Yards Bancorp, Inc. (NASDAQ:SYBT) for 7,135 shares. 1,488 were reported by Fifth Third Savings Bank. California State Teachers Retirement Systems reported 0% of its portfolio in Stock Yards Bancorp, Inc. (NASDAQ:SYBT). Susquehanna Intl Llp invested 0% of its portfolio in Stock Yards Bancorp, Inc. (NASDAQ:SYBT). Macquarie Grp Inc Ltd stated it has 1,500 shares. Alliancebernstein Ltd Partnership invested in 0% or 28,014 shares. Tower Capital Lc (Trc) accumulated 547 shares or 0% of the stock.

Director, Stephen Priebe is the Stock Yards Bancorp Inc’s insider which invested in shares of Stock Yards Bancorp Inc, 117 to be precise. The purchased shares were based on an average share price of $38.4, with the insider buying transaction valued at $4,493 U.S Dollars. Now, Stephen Priebe owns 16,477 shares which make up around 0.07% of Stock Yards Bancorp Inc’s market cap.

Since December 15, 2017, it had 42 insider purchases, and 1 insider sale for $208,340 activity. EDINGER CHARLES R III also bought $7,208 worth of Stock Yards Bancorp, Inc. (NASDAQ:SYBT) shares. $38 worth of Stock Yards Bancorp, Inc. (NASDAQ:SYBT) shares were bought by LECHLEITER RICHARD A. $3,582 worth of stock was bought by Priebe Stephen M on Friday, February 23. The insider Heitzman Donna L bought 98 shares worth $3,582. Shares for $2,515 were bought by Northern Richard on Tuesday, January 23. Shares for $412 were bought by TASMAN NORMAN on Wednesday, January 10. Herde Carl G had bought 49 shares worth $1,791.

The stock increased 0.13% or $0.05 during the last trading session, reaching $37.5. About 29,115 shares traded. Stock Yards Bancorp, Inc. (NASDAQ:SYBT) has declined 10.70% since May 1, 2017 and is downtrending. It has underperformed by 22.25% the S&P500.

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The company has market cap of $32.15 million. The companyÂ’s advanced product candidate is entolimod, a Toll-like receptor 5 agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It currently has negative earnings. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand.

Stock Yards Bancorp, Inc. (NASDAQ:SYBT) Ratings Chart